Physician profile
John Christopher Roe
NPI 1932596814
$20,419.28
in general payments reported to CMS, 2019-2025
9 companies · $14.29 in 2025
The $14.29 reported for 2025 was less than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $3,576 · 2021: $467 · 2022: $49.50 · 2025: $14.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medinc of Texas | $7,230.00 | 2019 | |
| Smith+Nephew, INC. | $5,041.10 | 2019-2020 | |
| Djo, LLC | $3,711.27 | 2019 | |
| Stryker Corporation | $2,090.94 | 2019-2021 | |
| Kairos Surgical INC | $1,868.04 | 2020 | |
| Zimmer Biomet Holdings, INC. | $424.64 | 2021-2022 | |
| Depuy Synthes Sales INC. | $19.67 | 2021 | |
| Horizon Therapeutics Plc | $19.33 | 2021 | |
| Polaris Technology Solutions LLC | $14.29 | 2025 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Roe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.